Antisense modulation of CD40 expression
AssigneeIsis Pharmaceuticals, Inc.
InventorsC. Frank Bennett, Lex M. Cowsert, Andrew M. Siwkowski
Life of this patent
Estimating the term…
Abstract
Antisense compounds, compositions and methods are provided for modulating the expression of CD40. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding CD40. Methods of using these compounds for modulation of CD40 expression and for treatment of diseases associated with CD40 are provided.
Claims46
An antisense compound 12 to 30 nucleobases in length comprising an at least 8 consecutive nucleobase portion complementary to an equal length portion within nucleobases 73 to 121 of a nucleic acid molecule encoding CD40 (SEQ ID NO:
- 85), wherein said compound is at least 90% complementary to SEQ ID NO:
- 85 as measured over the entirety of said antisense compound.
An antisense compound 12 to 30 nucleobases in length, wherein said compound comprises at least a 8 contiguous nucleobase portion of a sequence selected from the group consisting of SEQ ID NO:
- 6, SEQ ID NO:
- 7, SEQ ID NO:
- 8, SEQ ID NO:
- 9, SEQ ID NO:
- 10, SEQ ID NO:
- 11, SEQ ID NO:
- 12, and SEQ ID NO:
- 13.
A compound comprising an oligonucleotide consisting of 12 to 30 linked nucleosides having a nucleobase sequence comprising an at least 8 consecutive nucleobase portion complementary to an equal length portion within nucleobases 59-138 of SEQ ID NO:
- 85, wherein said compound is at least 90% complementary to SEQ ID NO:
- 85 as measured over the entirety of said oligonucleotide.
A compound comprising an oligonucleotide consisting of 12 to 25 linked nucleosides having a nucleobase sequence complementary to an equal length portion within nucleobases 63 to 100 of a nucleic acid molecule encoding CD40 having SEQ ID NO:
- 85, wherein said compound is 100% complementary to SEQ ID NO:
- 85 as measured over the entirety of said antisense compound.
Dependencies are inferred from the claim text.